Going through the exact same situation with Cigna. My employer dropped GLP-1 weight management coverage at renewal. I was on Zepbound, 7 months in, down 61 lbs.

What I ended up doing: switched to compounded tirzepatide through a telehealth provider. $199/month. My doctor wrote the prescription, the telehealth provider manages the compound Rx, and my PCP continues to monitor my labs and overall health.

Is it ideal? No, I preferred the brand medication. But $199/month is sustainable for me. $1,069/month for Zepbound is not. And the weight has continued to come off — lost another 11 lbs in the 2 months since switching.

Don't let the perfect be the enemy of the good. If your insurance pulls the rug out, compounded is a viable lifeline.

I'm posting anonymously because I don't want to identify my company, but I'm an HR Director and I want to give the employer perspective:

We dropped GLP-1 weight management coverage at our last renewal because our pharmacy costs for GLP-1s alone exceeded $2.1 million — that was 18% of our total pharmacy spend for a company of 1,200 employees. Our broker projected it would hit $3.5M next year.

I am not unsympathetic. I know these drugs work. I've seen employees' lives change. But when the choice is "raise everyone's premiums by $200/month" or "exclude one medication category," the math drives the decision.

What would change this: drug prices coming down, CMS allowing Medicare to negotiate GLP-1 prices (which would create downstream pressure on commercial pricing), or legislation requiring coverage. Until then, employers are in an impossible position.

I appreciate the honesty from the HR Director. I understand the cost pressure, even though it's devastating from the patient side.

Update for anyone following: My doctor submitted a PA for Ozempic coded for prediabetes/insulin resistance. It was approved by Anthem in 4 days. My copay is $45/month — actually LESS than I was paying for Wegovy ($65/month).

I'm stepping down from Wegovy 1.7mg to Ozempic 1mg (can titrate up to 2mg if needed). My doctor says the clinical difference at these doses is minimal.

So the crisis is averted for now. But I'm still going to push HR on this at the next benefits review. And I'll be looking at other employers during my next job search — GLP-1 coverage is now a benefits requirement for me, not a nice-to-have.